STERLING, Va.--(BUSINESS WIRE)--WaveLight, Inc. (FWB:WLT) announced today that the U.S. Food and Drug Administration (FDA) has approved wavefront-guided and mixed astigmatism indications for the ALLEGRETTO WAVE Eye-Q system. WaveLight’s second ALLEGRETTO WAVE system introduced in the U.S., the Eye-Q is the fastest laser vision correction platform available today. “We are pleased to provide surgeons with an even broader set of treatment options for the Eye-Q system,” said Wolfgang Tolle, CEO of WaveLight, Inc. “In accordance with our clinical philosophy, WaveLight’s ALLEGRETTO WAVE technology delivers consistent and superior outcomes on all platforms with either our proprietary Wavefront Optimized™ or wavefront-guided treatment modalities. We offer these choices so that the physician may determine which treatment is best suited for each individual patient.”
